%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
91 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T13:21:29Z
2024-03-29T06:47:46-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T06:47:46-07:00
application/pdf
Heather
200698.sept
uuid:2a27723a-1dd2-11b2-0a00-470927fd5800
uuid:2a27723c-1dd2-11b2-0a00-6a0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
113 0 obj
[117 0 R]
endobj
114 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(mycophenolic acid in vitro: Role of deoxyguanosine nucleotide)Tj
0 -1.25 TD
(depletion. Scan J Immunol 1991;33:161-73.)Tj
-2.175 -1.25 Td
[(18.)-875 (Corna D, Morigi M, Facchinetti D, Bertani )17.8 (T)74 (, Zoja C, Remuzzi G.)]TJ
2.175 -1.25 Td
(Mycophenolate mofetil limits renal damage and prolongs life in)Tj
T*
(murine lupus autoimmune disease. Kidney Int 1997;51:1583-9.)Tj
-2.175 -1.25 Td
[(19.)-875 (Sollinger HW)91.8 (, for the US. Renal )17.7 (T)34.9 (ransplant Mycophenolate Mofetil)]TJ
2.175 -1.25 Td
(Study Group: Mycophenolate mofetil for the prevention of acute)Tj
T*
(rejection in primary cadaveric renal allograft recipients.)Tj
T*
[(T)34.9 (ransplantation 1995;60:225-32.)]TJ
-2.175 -1.25 Td
[(20.)-875 (European Mycophenolate Mofetil Cooperative Study Group:)]TJ
2.175 -1.25 Td
(Placebo-controlled study of mycophenolate mofetil combined with)Tj
T*
(cyclosporine and glucocorticoids for prevention of acute rejection.)Tj
T*
(Lancet 1995;345:1321-5.)Tj
-2.175 -1.25 Td
[(21.)-875 (T)34.9 (ricontinental Mycophenolate Mofetil Renal )17.8 (T)34.9 (ransplantation Study)]TJ
2.175 -1.25 Td
[(Group: )54.9 (A)-219.8 (blinded, randomized clinical trial of mycophenolate)]TJ
T*
(mofetil for the prevention of acute rejection in cadaveric renal)Tj
0.0072 Tw T*
[(transplantation. T)34.9 (ransplantation )-17.8 (1996;61:1029-37.)]TJ
0.0249 Tw -2.175 -1.25 Td
[(22.)-875 (Briggs )17.7 (W)110.8 (A, Choi MJ, Scheel P)110.8 (. Successful mycophenolate mofetil)]TJ
2.175 -1.25 Td
[(treatment of glomerular disease. )54.9 (Am J Kidney Dis 1998;31: 213-7.)]TJ
-2.175 -1.25 Td
[(23.)-875 (Dooley MA, Cosio FG, Nachman PH, et al. Mychophenolate)]TJ
2.175 -1.25 Td
[(mofetil therapy in lupus nephritis: Clinical observations. J )54.8 (Am Soc)]TJ
T*
(Nephrol 1999;10:833-9.)Tj
-2.175 -1.25 Td
[(24.)-875 (Goldblum R. )17.8 (Therapy of rheumatoid arthritis with mycophenolate)]TJ
2.175 -1.25 Td
[(mofetil. Clin Exp Rheumatol 1993;1)36.9 (1 Suppl:S1)36.8 (17-S1)36.9 (19.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Zimmer)19.8 (-Molsber)17.8 (ger B, Knauf )17.7 (W)91.8 (, Eckhard )17.7 (T)74 (. Mycophenolate)]TJ
2.175 -1.25 Td
(mofetil for severe autoimmune hemolytic anemia. Lancet)Tj
0 Tw T*
(1997;350:1003-4.)Tj
0.02499 Tw 30.825 32.5 Td
[(26.)-875 (Nowack R, Birck R, van der )17.8 (W)79.8 (oude FJ. Mycophenolate mofetil for)]TJ
2.175 -1.25 Td
[(systemic vasculitis and IgA)-220.1 (nephropathy \(letter\). Lancet)]TJ
0 Tw T*
(1997;349:774.)Tj
0.0249 Tw -2.175 -1.25 Td
[(27.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries J. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Bombardieri C, Gladman DD, Urowitz Mb, Caron D, Chang CH,)]TJ
0 Tc 2.175 -1.25 Td
(and the Committee on Prognosis Studies in SLE: Derivation of the)Tj
T*
[(SLEDAI: a disease activity index for lupus patients. )54.9 (Arthritis)]TJ
T*
(Rheum 1992;35:630-40.)Tj
-2.175 -1.25 Td
[(29.)-875 (Pirsh JD, Sollinger HW)91.8 (. Mycophenolate mofetil: Clinical and)]TJ
2.175 -1.25 Td
[(experimental experience. )17.8 (Ther Drug Monit 1996;18:357-61.)]TJ
-2.175 -1.25 Td
[(30.)-875 (McDiarmid SV)74 (: Mycophenolate mofetil in liver transplantation.)]TJ
0.0072 Tw 2.175 -1.25 Td
[(Clin T)34.9 (ranspl )-17.8 (1996;10:140-5.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Sloan RP)110.7 (, Schwartz MM, Korbet SM, Borok RZ. Long-term)]TJ
0 Tc 2.175 -1.25 Td
(outcome in systemic lupus erythematosus membranous)Tj
T*
(glomerulonephritis. Lupus Nephritis Collaborative Study Group. )Tj
T*
[(J )54.9 (Am Soc Nephrol 1996;7:299-305.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Balow JE, Boumpas DT)73.9 (, )54.8 (Austin HA. Systemic lupus erythematosus)]TJ
0 Tc 2.175 -1.25 Td
[(and the kidney)64.9 (. Chapter 81. In: Lahita RG, editor)54.9 (. Systemic lupus)]TJ
T*
[(erythematosus, 3rd ed. Churchill Livingstone: New )36.9 (Y)100.1 (ork; 1998.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:9)Tj
0 Tw -46.2952 -0.0313 Td
(2108)Tj
ET
0 0 0 0 scn
/GS0 gs
104.01 59.08 407.5 -10.83 re
f*
0.5 w
104.01 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
78 0 obj
<>
endobj
96 0 obj
<>
endobj
45 0 obj
<>
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
68 0 obj
<>stream
HVpMg}9ބ(yȃsHIn-\t"WR
2)Lj1*]R;VC6֎b]1ء muTYܳsT;} 5P7^uwP:_(U]
UΨx#8 Ŝo yW}SqD+?#߭j~Ξ g}!Q_+ߢr+JluyU-j0[Z:IZQf"^+@Gutt38
j}ZR齥Zj0~
Tcv`4pYxv%.r(q%ËOAmNjXzNG>
pHYXU5,o`nbVbՌ)&)DƁǝE"{E¯1sQ#4⮘ #nV:l*Е>0q`V3n3g9.㊈bKŻ8-[YQ$2O3Tl➌isUn8MbL29[ߪBl]!섓K1u{"ZٻuDqf} E?O|_2RHC4e2[=^ּBȚc}s/;sN/b*0jv{1{g%+w{)qqwp"BDqDDdfybEX"bDe%B9E.<-W
$).:\"iBFVpbpj:d9H+ժYvP%0ؑ4vupMt؛zs#3 اy29\af? ( Tֹ3sŌ3@b&D#^
MfU⠸&nldtvf,Tȅr|K#7vGiʽ*mH%YUF)c2GYlS+;('f@yQԱBuz@=A2Dw:mvN03sswoO}lćIzqY%2NO!I8'QGGyFXF:D)NY%^Zp(A3JFij F4.-Shؓ6OZzhY3KO瑥b;]ٔk
bҸBWEZՔӎEW§{a/}s;bյ#/*d[xx#kv6rC:%/1zs\"w)r&fVPdәc:rZN +
QK(1JM_do!͌5r.=f+[_Sia0fňgsF3\ZThpm-I^[⛩P<0ǚL/p퉏4ZQ|.(&wB :{Ojq],Y{{=g^"?mE#UM@癅Ph0L4L),Kfx/5e67[%`/f?:0?\iifj*{M68$N6(L`:d.ݲ
L'c+luLOOFZ)}fCMtyy3x+m<-`.
mA!-+,Da֪W%>/VE2YP&y\ie}
bduӶ'bI]HDD@zAZBȳ>s2.6a{*o-p/kfeuHzO[8[Pa6obk(?@fTJ
cՖrJꮬBg
~u)YfOX.`|;Wۿ
͘}H.G/m*0阒dQz[eoIּy9?)/h)${~T3:7:*df8:ῬWlS;%vNnL'&
6l*Af -I!iE[:`aaee@dRӂ4!-&mTssmb>6rkuKX\cx
s9(c1 mǍGva]"QK!=許
|KSks%
wr7`BQ^+X-|}R؎Wc31֝=^={|>OcP=2?5'!˿'ڣ6ңzpLCL%FqwːWeQX/~ X|fg3ѕ:;d
Xa ?D@akgf>r#f93CwET'h>1HtdGa:'#HPt2dAl
Nt@N^k@:y(M'}@&H> I'{:uHn NvA0=@X';NvhYcd*k
6!o{ܮƭ[6e6!
|.nZfU2խ\V>V.nT[Q*h2تԵ*ZV)nkMX}X4RV?,~JqRد٬,d:pI<2~T%!_F~=_L8q0>q/Q;S#j%@ߏG G^ GϡWh!|&5D+"W ^wSq-m0e0j,XRfXrNiW=Swu=:9;)z#6 T_i8.i>p'I1U$zw:~=왠ؐ}/8흠/7$izC]K_mYhc/Of/BhHA/X!|MI>URbW%g4Lq~;aiYtRwF)v1O[$~*v)C)IbˤB)V*
Xde)gi,eA&p.lzf432
l&̲_V,npA$~k>>@/`70=NIYsKv*wTiJ=d/!>q5j<